Kerastem Technologies said today it won Investigative Device Exemption approval from the FDA to conduct a clinical trial of its Celution technology used to treat female and early male androgenic alopecia. The 70-patient phase II Style trial will follow-up on initial clinical work in Europe and Japan that the company used for IDE submission, the company […]